Resource Details

The PREVENT Cancer Drug Development Program is a National Cancer Institute-supported pipeline to bring new cancer prevention agents and interventions through preclinical development towards clinical trials. (See Structure and Governance.)

PREVENT is not a grant or a contract mechanism. Awardees will not necessarily receive any direct funding; rather NCI may allocate various resources and expertise towards implementation and development of approved, scientifically meritorious projects. Researchers in academia, government, industry, nationally and internationally can apply.

PREVENT is a high-performance program to stimulate, facilitate, and expedite movement of novel cancer preventive chemical or biological agents (singly or in combination) from the lab bench towards proof-of principle clinical testing.

PREVENT is an active NCI partnership with successful applicants to enable the milestone-driven progression of new cancer preventive small molecules, natural products, and biological agents towards clinical evaluation and registration.

PREVENT is a flexible entry-point system that will optimize and test an agent depending on the stage of development, with the goal of filing an Investigational New Drug Application with the U.S. Food and Drug Administration and entering it into clinical testing.